Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
Our 10 medical programs are spread across eight hospital sites – Princess Margaret, Toronto General, Toronto Rehab’s five sites, Toronto Western – as well as our education programs through the Michener Institute of Education at UHN. Learn more about the services, programs and amenities offered at each location.
Maps & Directions
Find out how to get to and around our nine locations — floor plans, parking, public transit, accessibility services, and shuttle information.
Ways You Can Help
Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It’s also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
A recent study from UHN experts has shed light on additional health concerns that people with a type of spinal arthritis called ankylosing spondylitis (AS) may face.
The study, 'Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study,' published online in the
Annals of Internal Medicine, links AS with a 35 per cent higher risk of dying from heart attack and a 60 per cent increased risk of dying from stroke than those without AS.
Drs. Nigil Haroon and Nisha Haroon, a husband and wife team at UHN, designed a population-based study including over 21,000 AS patients and 86,000 controls without AS to determine the level of mortality risk AS patients face.
"This research provides a bigger picture as to what patients with AS might face living with this disease," says Dr. Nigil Haroon, lead researcher and specialist in spondyloarthritis.
"The study shows that it is important that patients receive comprehensive screening, preventative care, as well as optimal management of cardiovascular and cerebrovascular disease."
This increased risk is particularly significant considering AS typically starts at a relatively young age of 20 to 40, much earlier than other forms of arthritis like rheumatoid arthritis.
AS is a type of inflammatory arthritis. Apart from inflammation, new bone formation is a major feature of AS. As a result, the bones of the spine begin to fuse together causing the spine to become very stiff and inflexible.
While there is no cure for AS, drug treatments known as biologics (engineered proteins derived from cells) have been shown to reduce symptoms and halt the progression of the disease.
Dr. Nigil Haroon led an international research study of 335 patients published in the leading rheumatology journal, Arthritis and Rheumatism, which showed a reduction of at least 50 per cent in the risk of progression of AS with the use of a type of biologic therapy.
"Another additional factor to consider is that male AS patients have 82 per cent higher risk of vascular mortality compared to females with AS," said Dr. Nigil Haroon.
"This further underscores the importance of understanding all of the additional health risks associated with AS and the need for more research to fully understand the connection between chronic inflammation and heart disease and stroke."